JP2015534946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534946A5 JP2015534946A5 JP2015536905A JP2015536905A JP2015534946A5 JP 2015534946 A5 JP2015534946 A5 JP 2015534946A5 JP 2015536905 A JP2015536905 A JP 2015536905A JP 2015536905 A JP2015536905 A JP 2015536905A JP 2015534946 A5 JP2015534946 A5 JP 2015534946A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- hemoglobin
- pharmaceutical composition
- cancerous tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 108010054147 Hemoglobins Proteins 0.000 claims 16
- 102000001554 Hemoglobins Human genes 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 239000001301 oxygen Substances 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 108010061951 Methemoglobin Proteins 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 3
- 229960004308 acetylcysteine Drugs 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- -1 is nonpyrogenic Substances 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 230000003639 vasoconstrictive effect Effects 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712853P | 2012-10-12 | 2012-10-12 | |
| US61/712,853 | 2012-10-12 | ||
| US13/713,031 US20140106004A1 (en) | 2012-10-12 | 2012-12-13 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| US13/713,031 | 2012-12-13 | ||
| PCT/US2013/064418 WO2014059199A1 (en) | 2012-10-12 | 2013-10-11 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534946A JP2015534946A (ja) | 2015-12-07 |
| JP2015534946A5 true JP2015534946A5 (enExample) | 2016-12-01 |
| JP6113850B2 JP6113850B2 (ja) | 2017-04-12 |
Family
ID=50475529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536905A Expired - Fee Related JP6113850B2 (ja) | 2012-10-12 | 2013-10-11 | がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140106004A1 (enExample) |
| EP (1) | EP2906222A4 (enExample) |
| JP (1) | JP6113850B2 (enExample) |
| KR (1) | KR20150065881A (enExample) |
| CN (1) | CN104717966B (enExample) |
| AP (1) | AP2015008315A0 (enExample) |
| AR (1) | AR093023A1 (enExample) |
| AU (1) | AU2013329121B2 (enExample) |
| BR (1) | BR112015007475A2 (enExample) |
| CA (1) | CA2884521C (enExample) |
| CL (1) | CL2015000897A1 (enExample) |
| EA (1) | EA201500301A1 (enExample) |
| IL (1) | IL237763A (enExample) |
| MA (1) | MA37994A2 (enExample) |
| MX (1) | MX367562B (enExample) |
| PH (1) | PH12015500562A1 (enExample) |
| SG (3) | SG11201502133SA (enExample) |
| TW (1) | TW201414489A (enExample) |
| UY (1) | UY35082A (enExample) |
| WO (1) | WO2014059199A1 (enExample) |
| ZA (1) | ZA201501949B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201509042YA (en) * | 2013-05-13 | 2015-12-30 | Vision Global Holdings Ltd | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| EP3154694B1 (en) | 2014-06-13 | 2025-01-29 | Children's Medical Center Corporation | Products and methods to isolate mitochondria |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| EP3383411B1 (en) | 2015-11-30 | 2025-07-09 | Sana Biotechnology, Inc. | Sub-mitochondrial particles for use in treating metabolic conditions |
| ES3057779T3 (en) | 2016-01-15 | 2026-03-04 | Childrens Medical Ct Corp | Therapeutic use of mitochondria and combined mitochondrial agents |
| US20230190947A1 (en) * | 2016-06-21 | 2023-06-22 | Therapure Biopharma Inc. | Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer |
| WO2018195434A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| WO2018195446A1 (en) * | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| US11160821B2 (en) | 2017-05-19 | 2021-11-02 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| CU20190106A7 (es) | 2017-06-26 | 2020-11-30 | Lunella Biotech Inc | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
| JPWO2019124423A1 (ja) * | 2017-12-19 | 2020-10-22 | 国立大学法人 岡山大学 | がんの進行抑制、治療、予防及び／又は再発予防剤 |
| CN111558032B (zh) * | 2020-05-19 | 2023-08-22 | 中国科学院宁波材料技术与工程研究所 | 一种蛋白纳米药物及其制备方法与应用 |
| CN114344263B (zh) * | 2022-02-21 | 2023-08-01 | 杭州普略生物科技有限公司 | 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用 |
| KR102793996B1 (ko) | 2022-03-31 | 2025-04-09 | 충남대학교산학협력단 | 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물 |
| WO2025222059A1 (en) * | 2024-04-17 | 2025-10-23 | Prolong Pharmaceuticals Llc | Method of treating cancer using pegylated bovine hemoglobin |
| CN119746044A (zh) * | 2025-03-06 | 2025-04-04 | 润方（北京）生物医药研究院有限公司 | 血红蛋白氧载体在制备抗病毒药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| CN1741821B (zh) * | 2002-10-29 | 2011-08-10 | 恩根尼公司 | 用于癌症治疗的组合物 |
| CA2750639A1 (en) * | 2009-01-23 | 2010-07-29 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
| LT2440239T (lt) * | 2009-06-09 | 2017-12-11 | Prolong Pharmaceuticals, LLC | Hemoglobino kompozicijos |
| EP2451459B1 (en) * | 2009-07-07 | 2017-11-22 | Normoxys, Inc. | Method of reducing multi-drug resistance using inositol tripyrophosphate |
| US8808748B2 (en) * | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US20110319332A1 (en) * | 2010-06-23 | 2011-12-29 | Bing Lou Wong | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US7932356B1 (en) * | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
-
2012
- 2012-12-13 US US13/713,031 patent/US20140106004A1/en not_active Abandoned
-
2013
- 2013-10-11 SG SG11201502133SA patent/SG11201502133SA/en unknown
- 2013-10-11 KR KR1020157012185A patent/KR20150065881A/ko not_active Ceased
- 2013-10-11 AP AP2015008315A patent/AP2015008315A0/xx unknown
- 2013-10-11 MX MX2015004512A patent/MX367562B/es active IP Right Grant
- 2013-10-11 CA CA2884521A patent/CA2884521C/en active Active
- 2013-10-11 EA EA201500301A patent/EA201500301A1/ru unknown
- 2013-10-11 SG SG10201607846PA patent/SG10201607846PA/en unknown
- 2013-10-11 JP JP2015536905A patent/JP6113850B2/ja not_active Expired - Fee Related
- 2013-10-11 EP EP13844670.3A patent/EP2906222A4/en not_active Ceased
- 2013-10-11 MA MA37994A patent/MA37994A2/fr unknown
- 2013-10-11 CN CN201380053346.1A patent/CN104717966B/zh not_active Expired - Fee Related
- 2013-10-11 SG SG10201608747RA patent/SG10201608747RA/en unknown
- 2013-10-11 BR BR112015007475A patent/BR112015007475A2/pt not_active IP Right Cessation
- 2013-10-11 AU AU2013329121A patent/AU2013329121B2/en not_active Ceased
- 2013-10-11 WO PCT/US2013/064418 patent/WO2014059199A1/en not_active Ceased
- 2013-10-14 UY UY35082A patent/UY35082A/es not_active Application Discontinuation
- 2013-10-14 TW TW102136951A patent/TW201414489A/zh unknown
- 2013-10-15 AR ARP130103741A patent/AR093023A1/es unknown
-
2014
- 2014-06-19 US US14/308,725 patent/US9056098B2/en active Active
-
2015
- 2015-03-16 IL IL237763A patent/IL237763A/en active IP Right Grant
- 2015-03-16 PH PH12015500562A patent/PH12015500562A1/en unknown
- 2015-03-20 ZA ZA2015/01949A patent/ZA201501949B/en unknown
- 2015-04-09 CL CL2015000897A patent/CL2015000897A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rejhová et al. | Natural compounds and combination therapy in colorectal cancer treatment | |
| ES2989617T3 (es) | Moduladores de receptores de quimioquinas y usos de los mismos | |
| CA2884521C (en) | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence | |
| Oliansky et al. | The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review | |
| JP2019525898A5 (enExample) | ||
| EA201101155A1 (ru) | Способ приготовления фармацевтической композиции, содержащей теплостойкий переносчик кислорода | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2013189456A5 (enExample) | ||
| PH12015502536A1 (en) | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | |
| JP2009510165A5 (enExample) | ||
| MX2016010095A (es) | Beta-aminoacidos beta-sustituidos y sus analogos como agentes quimioterapeuticos. | |
| AR101101A1 (es) | Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer | |
| MY169908A (en) | A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications | |
| JP2018522880A5 (enExample) | ||
| JP2016503026A5 (enExample) | ||
| JP2016502527A5 (enExample) | ||
| RU2013149175A (ru) | Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы | |
| JP2011513378A5 (enExample) | ||
| JP2013227347A5 (enExample) | ||
| Greenhill | Gemcitabine confirmed as the first-line therapy for pancreatic cancer | |
| FANG et al. | Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer | |
| RU2018143803A (ru) | Со-кристаллы и содержащие их фармацевтические композиции | |
| Wu et al. | MCT-1 expression promotes neoplastic multinucleation through the Src/p190B signaling activation in triple-negative breast cancer cells | |
| Sellar's | Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lowerrisk del (5q) MDS. | |
| Knochel et al. | Fluorination of Nickel (II)–Aryl Complexes with [18F] Fluoride |